Evolution of Protein Design
Protein design has evolved tremendously over the last 20 years and Rosetta has been at the bleeding edge throughout that time. Rosetta was first at most major protein design achievements, such as protein stabilization, affinity, enzyme specificity, novel protein assemblies, and even entirely new protein structures with no sequence similarity to natural proteins.
At Cyrus, we have built a proprietary software platform which uses the most successful design tools to engineer novel non-antibody biologics by designing existing proteins.
Evolution of protein design
Protein design has evolved tremendously over the last 20 years and Rosetta has been at the bleeding edge throughout that time. Rosetta was first at most major protein design achievements, such as protein stabilization, affinity, enzyme specificity, novel protein assemblies, and even entirely new protein structures with no sequence similarity to natural proteins.
At Cyrus, we have built a proprietary software platform which uses the most successful design tools to engineer novel non-antibody biologics by designing existing proteins
“THERE IS THIS ENORMOUS SPACE OF POSSIBLE PROTEINS THAT EVOLUTION HASN’T EXPLORED. WHAT WE ARE TRYING TO DO IS TO BUILD PROTEINS FROM SCRATCH.”
David Baker (April 2022 Talk at Foresight Institute)
Our design platform’s technical capabilities are focused on the following areas:
- Broad range of structure prediction using Rosetta + Machine Learning/AI
- Immunogenicity reduction (immunogenicity can cause life threatening reactions, limits efficacy)
- Increasing stability and serum half-life (short half life necessitates more frequent infusions)
- Increasing solubility & reducing aggregation (impacts drug administration & manufacturing complexity)
- Target binding affinity (enhances efficacy)
- Binding specificity (enhances efficacy and reduces off-target effects)
This platform includes:
- Complete redesign and engineering of natural proteins
- Design of novel functional characteristics, such as modified binding specificity of protein/protein interactions
- Increasing biologic efficacy, e.g. via increased target affinity
- Enhancing safety, e.g. via decreased binding to off-target proteins
- Reducing immunogenicity
INTERESTED IN
PARTNERING WITH US ON
PROTEIN THERAPEUTICS?